Skip to main content
. Author manuscript; available in PMC: 2018 Mar 8.
Published in final edited form as: Nano Lett. 2016 Dec 5;17(3):1326–1335. doi: 10.1021/acs.nanolett.6b03329

Figure 5.

Figure 5

Incorporating LPS in the LNPs increases both the CD 8 T cell levels and antitumor activity. LNPs were formulated at the same lipid ratio as formulation B-11, but 1 mol percent of PEG was replaced with 1 mol percent of LPS. (A) Left: LNPs containing 1.0 μg of LPS per dose, formulated with OVA mRNA, increase the CD8 T cell levels 8 days after the immunization. Right: Representative FACS profiles day 8 (*P < 0.05 by ordinary one-way ANOVA Bonferroni’s multiple comparisons test). (B) In the B16 F10 tumor model, LPS containing LNPs, formulated with TRP2 mRNA, induce tumor shrinkage as compared to the slower tumor growth by TRP2 mRNA formulated in the B-11 formulation (***P < 0.001, ****P < 0.0001, as compared with the B-11 irrelevant mRNA LPS group, two-way ANOVA with Bonferroni posthoc). (C) The LPS containing LNPs lead to longer overall survival (* P < 0.05, ** P < 0.01, as compared with the untreated control group, Mantel Cox test). β-Galactosidase mRNA was used as the irrelevant control for the studies reported in the figure.